Every 10-Q that GRAIL, Inc. (GRAL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GRAL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRAL filings page.
GRAIL, Inc. (GRAL) reported Q3 2025 results. Total revenue was $36,194 (thousands), up from $28,652 (thousands) a year ago, driven mainly by screening revenue of $32,807 (thousands). Net loss narrowed to $88,977 (thousands), or $2.46 per share, from $125,688 (thousands) a year earlier as operating expenses declined.
Cash and cash equivalents were $126,892 (thousands) and short‑term marketable securities were $413,238 (thousands) as of September 30, 2025. Year‑to‑date, operating cash use was $235,222 (thousands). Management states existing cash, cash equivalents, and short‑term marketable securities will be sufficient for at least the next 12 months. Total assets were $2,601,031 (thousands) with stockholders’ equity of $2,239,963 (thousands). As of November 10, 2025, common shares outstanding were 38,982,223.
GRAIL, Inc. (GRAL) reported Q2 2025 results showing revenue growth and materially smaller operating losses versus prior-year periods after large pushdown impairments in 2024. Total revenue was $35.5 million for the quarter and $67.4 million for the six months, driven mainly by screening revenue. Net loss was $114.0 million for the quarter and $220.2 million for six months, versus multi‑hundred‑million and billion‑level losses in 2024 primarily from goodwill and IPR&D impairments. The balance sheet shows $130.8 million of cash and restricted cash and $475.3 million of short‑term marketable securities; management believes these resources are sufficient to fund operations for at least 12 months. The company completed its Spin‑Off from Illumina, received $932.3 million of disposal funding subject to a time‑limited clawback, and disclosed positive registrational trial signals (NHS‑Galleri prevalent round and initial PATHFINDER 2 top‑line results). Significant amortization and prior impairment charges continue to affect reported operating results and accumulated deficit.